Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 41, Issue 2 SUPPL., 2002, Pages 26S-49S

[No Author Info available]

Author keywords

Amphetamine; Attention deficit hyperactivity disorder; Methylphenidate; Pemoline; Stimulants

Indexed keywords

CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHYLPHENIDATE; PEMOLINE; AMPHETAMINE DERIVATIVE; PSYCHOTROPIC AGENT;

ATTENTION DEFICIT DISORDER; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; NARCOLEPSY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ADOLESCENT; ADULT; BRAIN; CHILD; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MONITORING; HUMAN; PRESCHOOL CHILD; PSYCHOPHARMACOLOGY; UNITED STATES;

ADOLESCENT; ADULT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; METHYLPHENIDATE; NARCOLEPSY; PEMOLINE; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 0036483615     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Abikoff H, Gittelman R (1985), Hyperactive children treated with stimulants: is cognitive training a useful adjunct? Arch Gen Psychiatry 42:953-961
2. Achenbach T (1991), Manual for the Child Behavior Checklist/4-18 and 1991 Profile. Burlington: University of Vermont Department of Psychiatry
3. American Academy of Child and Adolescent Psychiatry (1997a), Practice parameters for the assessment and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36:85S-121S
4. American Academy of Child and Adolescent Psychiatry (1997b), Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 36:69S-84S
5. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
6. Angold A, Erkanli A, Egger H, Costello J (2000), Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 39:975-983
7. Angrist BM, Gershon S (1972), Psychiatric sequelae of amphetamine use. In: Psychiatric Complications of Medical Drugs, Shader RI, ed. New York: Raven, pp 175-199
8. Arnold L (2000), Methylphenidate vs amphetamine: comparative review. J Attention Disord 3:200-211
9. Arnold L, Abikoff H, Cantwell D et al. (1997), NIMH Collaborative Multimodal Treatment Study of Children With ADHD (MTA): design, methodology, and protocol evolution. J Attention Disord 2:141-158
10. Arnold LE, Christopher J, Huestis R, Smeltzer D (1978), Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction. Arch Gen Psychiatry 35:463-473
11. Barkley R (1988), The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry 27:336-334
12. Barkley R (1990a), Child behavior rating scales and checklists. In: Assessment end Diagnosis in Child Psychopathology, Rutter M, Tuma AH, Lann IS, eds. New York: Guilford, pp 113-155
13. Barkley R, DuPaul G, Connor D (1999), Stimulants. In: Practitioner's Guide to Psychoactive Drugs for Children and Adolescents, 2nd ed, Werry J, Aman M, eds. New York: Plenum, pp 213-241
14. Barkley R, McMurray M, Edelbroch C, Robbins K (1990), Side effects of MPH in children with attention deficit hyperactivity disorder: a systematic placebo-controlled evaluation. Pediatrics 86:184-192
15. Barkley RA (1977), A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18:137-165
16. Barkley RA (1982), Hyperactive Children: A Handbook for Diagnosis and Treatment. New York: Guilford
17. Barkley RA (1990b), Behavior rating scales. In: Attention-Deficit/ Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York: Guilford, pp 278-326
18. Barkley RA (1997), ADHD and the Nature of Self-Control. New York: Guilford
19. Barkley RA, Karlsson J, Strzilecki E (1984), Effects of age and Ritalin dosage on mother-child interactions of hyperactive children. J Consult Clin Psychol 52:750-758
20. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911-916
21. Berkovitch M, Pope E, Phillips J, Koren G (1995), Pemoline-associated fulminant liver failure: testing the evidence for causation. Clin Pharmacol Ther 57:696-698
22. Biederman J (1991), Sudden death in children treated with a tricyclic antidepressant: a commentary. Biol Ther Psychiatry Newsl 14:1-4
23. Biederman J, Newcorn J, Sprich S (1991), Comorbidiry of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am Psychiatry 148:564-577
24. Birmaher BB, Greenhill L, Cooper T, Fried J, Maminski B (1989), Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 28:768-772
25. Bradley C (1937), The behavior of children receiving benzedrine. Am J Psychiatry 94:577-585
26. Bradley C, Bowen M (1941), Amphetamine (benzedrine) therapy of children's behavior disorders. Am J Orthopsychiatry 11:92-103
27. Brown T (1996), Brown Attention Deficit Disorder Scales: Manual. San Antonio, TX: Psychological Corporation
28. Buitelaar J, Gary R, Swaab-Barneveld H, Kuiper M (1995), Prediction of clinical response to methylphenidate in children with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:1025-1032
29. Burke MS, Josephson A, Lightsey A (1995), Combined methylphenidate and imipramine complication (letter). J Am Acad Child Adolesc Psychiatry 34:403-404
30. Campbell M, Small A, Green W (1984), Behavioral efficacy of haloperidol and lithium carbonate. Arch Gen Psychiatry 41:650-656
31. Campbell S, Ewing L (1990), Follow-up of hard-to-manage preschoolers: adjustment at age 9 and predictors of continuing symptoms. J Child Psychol Psychiatry 31:871-879
32. Carlson GA, Loney J, Salisbury H, Kramer JR, Arthur C (2000), Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study. J Child Adolesc Psychopharmacol 10:175-184
33. Castellanos X, Giedd J, Elia J et al. (1997), Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 36:589-596
34. Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM (1983), Methylphenidate hydrochloride given with or before breakfast, II: effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 72:56-59
35. Cohen LG, Prince J, Biederman J et al. (1999), Absence of effect of stimulants on the pharmacokinetics of desipramine in children. Pharmacotherapy 19:746-752
36. Cohen N, Sullivan J, Minde K, Novack C, Helwig C (1981), Evaluation of the relative effectiveness of methylphenidate and cognitive behavior modification in the treatment of kindergarten-aged hyperactive children. J Abnorm Child Psychol 9:43-54
37. Conners CK (1975), Controlled trial of methylphenidate in preschool children with minimal brain dysfunction. Int J Ment Health 4:61-74
38. Conners CK (1997), Conners' Rating Scales-Revised. Toronto: Multi-Health Systems
39. Conners CK (1998), Rating scales in attention deficit/hyperactivity disorder. J Clin Psychiatry 59(suppl 7):24-30
40. Conners CK, Eisenberg L, Barcai A (1967), Effect of dextroamphetamine on children: studies on subjects with learning disabilities and school behavior problems. Arch Gen Psychiatry 17:478-485
41. Connor DF, Fletcher KE, Swanson J (1999), A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 38:1551-1559
42. Cox BM (1990), Drug tolerance and physical dependence. In: Principles of Drug Action: The Basis of Pharmacology, Pratt WB, Taylor P, eds. New York: Churchill Livingstone, pp 639-690
43. DeVane C, MarkowitzJS, Carson SW et al. (2000), Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol 20:347-349
44. Diamond I, Tannock R, Schachar R (1999), Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 38:402-409
45. Donovan SJ, Stewart JW, Nunes EV et al. (2000), Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 157:818-820
46. Dulcan M (1990), Using psychostimulants to treat behavior disorders of children and adolescents. J Child Adolesc Psychopharmacol 1:7-20
47. Dunnick J, Hailey J (1995), Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology 103:77-84
48. DuPaul G, Barkley R, McMurray M (1994), Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry 33:894-903
49. DuPaul GJ, Barkley RA (1990), Medication therapy. In: Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, Barkley RA, ed. New York: Guilford, pp 573-612
50. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998), ADHD Rating Scales-IV: Checklists, Norms and Clinical Interpretation. New York: Guilford
51. Eisenberg L, Lachman R, Molling P, Lockner A, Mizelle J, Conners C (1961), A psychopharmacologic experiment in a training school for delinquent boys: methods, problems and findings. Am J Orthopsychiatry 33:431-447
52. Elia J, Borcherding B, Rapoport J, Keysor C (1991), Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders? Psychiatry Res 36:141-155
53. Ernst M, Liebenauer L, Jons P, Murphy D, Zametkin A (1995), L-Deprenyl on behavior and plasma monoamine metabolites in hyperactive adults. Psychopharmacol Bull 31:565
54. Firestone P, Monteiro-Musten L, Pisterman S, Mercer J, Bennet S (1998), Short-term side effects of stimulant medication are increased in preschool children with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 8:13-25
55. Frazier JA, Meyer MC, Biederman J et al. (1999), Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965
56. Frierson RL, Wey JJ, Tabler JB (1991), Psychostimulants for depression in the medically ill. Am Fam Phys 43:163-170
57. Gadow K, Sverd J, Sprafkin J, Nolan E, Ezor S (1995), Efficacy of methylphenidate for attention deficit hyperactivity in children with tic disorder. Arch Gen Psychiatry 52:444-455
58. Gillberg C, Melander H, von Knorring A et al. (1997), Long-term central stimulant treatment of children with attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Arch Gen Psychiatry 54:857-864
59. Gittelman-Klein R (1980), Diagnosis and drug treatment of childhood disorders: attention deficit disorder with hyperactivity. In: Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children, Klein DF, Gittelman-Klein R, Quitkin F, Rifkin A, eds. Baltimore: Williams & Wilkins
60. Gittelman-Klein R (1987), Pharmacotherapy of childhood hyperactivity: an update. In: Psychopharmacology: The Third Generation of Progress, Meltzer HY, ed. New York: Raven
61. Gittelman-Klein R, Landa B, Mattes JA, Klein DF (1988), Methylphenidate and growth in hyperactive children. Arch Gen Psychiatry 45:1127-1130
62. Goldman L, Genel M, Bezman R, Slanetz P (1998), Diagnosis and treatment of attention-deficit/hyperactiviry disorder. JAMA 279:1100-1107
63. Grace T (2000), Cellular and molecular neurochemistry of psychostimulant effects on dopamine. In: The Neuropharmacology of Pychostimulant Drugs: Implications for ADHD, Solanto M, Castellanos X, eds. New York: Oxford University Press, pp 85-100
64. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B (1998), Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 79:1047-1050
65. Greenhill L (1998a), Childhood attention deficit hyperactivity disorder: pharmacological treatments. In: Treatments That Work, Nathan PE, Gorman J, eds. Philadelphia: Saunders, pp 42-64
66. Greenhill L (1998b), The use of psychoactivc medications in preschoolers: indications, safety and efficacy. Can J Psychiatry 43:576-581
67. Greenhill L, Abikoff H, Conners CK et al. (1996), Medication treatment strategies in the MTA: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 35:444-454
68. Greenhill LL, MTA Cooperative Group (1999), Chronic Stimulant Treatment Effects of Weight Acquisition Rates of ADHD Children. Boca Raton, FL: New Clinical Drug Evaluation Unit Program Conference Proceeding 39:26-27
69. Gualtieri CT (1991), Neuropsychiatry and Behavioral Pharmacology. New York: Springer-Verlag
70. Gualtieri CT, Kanoy R, Koriath U et al. (1981), Growth hormone and prolactin secretion in adults and hyperactive children relation to methylphenidate serum levels. Psychoneuroendocrinology 6:331-339
71. Gualtieri CT, Wargin W, Kanoy R et al. (1982), Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry 21:19-26
72. Handen BL, Feldman JM, Lurier A, Murray PJH (1999), Efficacy of methylphenidate among preschool children with developmental difficulties. J Am Acad Child Adolesc Psychiatry 38:805-812
73. Hinshaw S, Heller T, McHale J (1992), Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphenidate. J Consult Clin Psychol 60:274-281
74. Hinshaw S, Henker B, Whalen C, Ehrardy D, Dunnington RE (1989), Aggressive, prosocial and nonsocial behavior in hyperactive boys: dose effects of MPH in naturalistic settings. J Consult Clin Psychol 57:636-643
75. Jacobvitz D, Srouge LA, Stewart M, Leffert N (1990), Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 29:677-688
76. Jensen P, Kettle L, Roper M et al. (1999), Are stimulants overprescribed? Treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 38:797-804
77. Kent J, Blader J, Koplewicz H, Abikoff H, Foley C (1995), Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 96:320-325
78. Klein R, Abikoff H, Klass E, Ganales D, Seese L, Pollack S (1997), Clinical efficacy of methylphenidate in conduct disorder with and without atten tion deficit hyperactivity disorder. Arch Gen Psychiatry 54:1073-1080
79. Kutcher S (1986), Assessing and treating attention deficit disorder in adolescents: the clinical application of a single-case research design. Br J Psychiatry 149:710-715
80. Lambert NM, Hartsough CS (1998), Prospective study of tobacco smoking and substance dependence among samples of ADHD and non-ADHD subjects. J Learn Disabil 31:533-544
81. Laufer MW, Denhoff E, Solomon G (1957), Hyperkinetic impulsive disorder in children's behavior problems. Psychosom Med 19:38-49
82. Law SF, Schachar R (1999), Do typical clinical doses of methylphenidate cause tics in children treated for attention deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 38:944-951
83. LeFever G, Sawson KV, D, Morrow AL (1999), The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health 89:1359-1364
84. Loney J, Milich R (1982), Hyperactivity, inattention, and aggression in clinical practice. In: Advances in Developmental and Behavioral Pediatrics, Vol 3, Gadow K, Bialer I, eds. Greenwich, CT: JAI Press
85. Manuzza S, Klein R, Bonagura N, Malloy P, Giampino T, Addlii K (1991), Hyperactive boys almost grown up, V: replication of psychiatric status. Arch Gen Psychiatry 48:77-83
86. Matochik J, Nordahl T, Gross M et al. (1993), Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology 8:377-386
87. Mattes JA, Boswell J, Oliver H (1984), Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 41:449-456
88. Mayes S, Crites D, Bixler E, Humphrey B, Mattison R (1994), Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status. Dev Med Child Neurol 36:1099-1107
89. McDougle CJ, Holmes JP, Bronson MR et al. (1997), Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693
90. McMaster University Evidence-Based Practice Center (1998), The Treatment of Attention-Deficit/Hyperactivity Disorder: An Evidence Report (Contract 290-97-0017). Washington, DC: Agency for Health Care Policy and Research
91. Mitler MM, Hajdukovic R (1990), Narcolepsy. J Clin Neurophysiol 7:93-118
92. Montieiro-Musten L, Firestone P, Pisterman S, Bennet S, Mercer J (1997), Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry 36:1407-1415
93. MTA Cooperative Group (1999a), 14-Month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
94. MTA Cooperative Group (1999b), Moderators and mediators of treatment response for children with ADHD: the MTA study. Arch Gen Psychiatry 56:1088-1096
95. Murphy DA, Pelham WE, Lang AR (1986), Methylphenidate effects on aggressiveness in ADD and ADD/CD children. Presented at the American Psychological Association, Washington, DC
96. NIH Consensus Statement (1998), Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). NIH Consens Statement 16:1-37
97. Page JG, Bernstein JE, Janicki RS, Michelli FA (1974), A multicenter trial of pemoline (Cylert) in childhood hyperkinesis. In: Clinical Use of Stimulant Drugs in Children, Conners, CK ed. The Hague: Excerpta Medica
98. Pataki C, Carlson G, Kelly K, Rapport M (1993), Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 32:1065-1072
99. Patrick KS, Mueller RA, Gualtieri CT, Breese GR (1987), Pharmacokinetics and actions of methylphenidate. In: Psychopharmacology: A Third Generation of Progress, Meltzer HY, ed. New York: Raven, pp 1387-1395
100. Pelham WE, Burrows-Maclean L, Gnagy EM et al. (2000), Once-a-day Concerta methylphenidate versus t.i.d. methylphenidate in natural settings: safety and efficacy. Pediatrics 121:126-137
101. Pelham WE, Greenslade KE, Vodde-Hamilton MA et al. (1990a), Relative efficacy of long-acting stimulants on ADHD children: a comparison of standard methylphenidate, Ritalin-SR, Dexedrine spansule, and pemoline. Pediatrics 86:226-237
102. Pelham WE, McBurnett K, Harper G et al. (1990b), Methylphenidate and baseball playing in ADD children: who's on first? J Consult Clin Psychol 22:131-135
103. Pelham WE, Milich R (1991), Individual differences in response to Ritalin in classwork and social behavior. In: Ritalin: Theory and Patient Management, Greenhill LL, Osman B, eds. New York: Mary Ann Liebert, pp 203-222
104. Pelham WE, Sturges J, Joza Jeal (1989), The effects of sustained release 20 and 10 mg Ritalin b.i.d. on cognitive and social behavior in children with attention deficit disorder. Pediatrics 80:491-501
105. Pelham WE, Swanson J, Furman M, Schwindt H (1995), Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 34:1504-1513
106. Pelham WE, Waschbusch DA (1999). Behavioral interventions in attention deficit/hyperactivity disorder. In: Handbook of Disruptive Behavior Disorders, Quay H, Hogan A, eds. New York: Kluwer Academic/Plenum Publishers, pp 255-278
107. Perel JM, Greenhill LL, Curran S, Feldman B, Puig-Antich J (1991), Correlates of pharmacokinetics and attentional measures in methylphenidate treated hyperactive children. Clin Pharmacol Ther 49:160-161
108. Physicians' Desk Reference (2000), Montvale, NJ: Medical Economics Company
109. Pliszka SR (1992), Comorbidity of attention-deficit hyperactivity disorder and overanxious disorder. J Am Acad Child Adolesc Psychiatry 31:197-203
110. Pliszka SR (2000), Comparing the effects of stimulant and non-stimulant agents on catecholamine function: implications for theories of attention deficit hyperactivity disorder (ADHD). In: The Neuropharmacology of Psychostimulant Drugs: Implications for AD/HD, Solanto M, Castellanos X, eds. New York: Oxford University Press, pp 141-160
111. Pliszka SR, Greenhill LL, Crismon ML et al. (2000a), The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder, part I. J Am Acad Child Adolesc Psychiatry 39:908-919
112. Pliszka SR, Greenhill LL, Crismon L et al. (2000b), The Texas Children's Medication Algorithm Project: Report of the Texas Expert Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder, part II: tactics. J Am Acad Child Adolesc Psychiatry 39:920-927
113. Popper CW, Zimnitzky B (1995), Sudden death putativdy related to desipramine treatment in youth: a fifth case and a review of speculative mechanisms. J Child Adolesc Psychopharmacol 5:283-300
114. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn P, Ludlow C, Mikkelsen EJ (1980), Dextroamphetamine: cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943
115. Rapport M, Carlson G, Kelly K, Pataki C (1993), Methylphenidate and desipramine in hospitalized children, I: separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 32:333-342
116. Rapport MD, DuPaul GJ, Kelly KL (1989), Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacol Bull 25:285-290
117. Ratey J, Greenberg MS, Bemporad JR, Lindem K (1992), Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol 2:267-275
118. Richters J, Arnold L, Abikoff H et al. (1995), The National Institute of Mental Health Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit Hyperactivity Disorder (MTA), I: background and rationale. J Am Acad Child Adolesc Psychiatry 34:987-1000
119. Robinson TE, Camp DM (1987), Long-lasting effects of escalating doses of d-amphetamine on brain monoamines, amphetamine-induced stereo-typed behavior and spontaneous nocturnal locomotion. Pharmacol Biochem Behav 26:821-827
120. Rosenberg PB, Ahmed I, Hurwitz S (1991), Methylphenidate in depressed medically ill patients. J Clin Psychiatry 52:263-267
121. Sabelsky D (1990), Fluoxetine in adults with residual attention deficit disorder and hypersomnolence. J Neuropsychiatry Clin Neurosci 2:463-464
122. Safer D, Zito J, Fine E (1996), Increased methylphenidate usage for attention deficit hyperactivity disorder in the 1990s. Pediatrics 98:1084-1088
123. Safer DJ, Allen RP (1989), Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children. J Pediatr 115:1003-1008
124. Sallee F, Stiller R, Perel J (1992), Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 31:244-251
125. Sallee FR, Stiller R, Perel J, Bates T (1985), Oral pemoline kinetics in hyperactive children. Clin Pharmacol Ther 37:606-609
126. Satterfield JH, Cantwell DP, Satterfield BT (1979), Multimodality treatment: a one-year follow-up of 84 hyperactive boys. Arch Gen Psychiatry 36:965-974
127. Schachar R, Tannock R (1993), Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychopharmacol 3:81-97
128. Schachar R, Tannock R, Cunningham C, Corkum P (1997), Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 36:754-763
129. Schleiffer M, Weiss G, Cohen N, Elman M, Cvejic H, Kruger E (1975), Hyperactivity in preschoolers and the effect of methylphenidate. Am J Orthopsychiatry 45:38-50
130. Schmidt K, Solanto MV, Sanchez-Kappraff M, Vargas P, Wein S (1984), The effect of stimulant medication on academic performance, in the context of multimodal treatment, in attention deficit disorders with hyperactivity: two case reports. J Clin Psychopharmacol 4:100-103
131. Sebrechts MM, Shaywirz SE, Shaywitz BA, Jatlow P, Anderson GM, Cohen DJ (1986), Components of attention, methylphenidate dosage, and blood levels in children with attention deficit disorder. Pediatrics 77:222-228
132. Sherman M (1991), Prescribing practice of methylphenidate: the Suffolk County study. In: Ritalin: Theory and Patient Management, Osman B, Greenhill LL, eds. New York: Mary Ann Liebert, pp 401-420
133. Shuster L, Hudson J, Anton M, Right D (1982), Sensitization of mice to methylphenidate. Psychopharmacology 71:31-36
134. Spencer T, Biederman J, Harding M, Faraone S, Wilens T (1996a), Growth deficits in ADHD children revisited: evidence for disorder related growth delays. J Am Acad Child Adolesc Psychiatry 35:1460-1467
135. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S (1996b), Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432
136. Spencer T, Biederman J, Wilens T, Prince J (1995a), Effectiveness and tolerability of tomoxetine in adults with attention-deficit/hyperactivity disorder. In: Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry 11:109
137. Spencer T, Wilens T, Biederman J, Faraone S, Ablon JS, Lapey K (1994), A double-blind comparison of MPH and placebo in adults with attention deficit hyperactivity disorder (ADHD). In: Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry 9:42
138. Spencer T, Wilens T, Biederman J, Faraone S, Ablon JS, Lapey K (1995b), A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood onset ADHD. Arch Gen Psychiatry 52:434-443
139. Sprague RL, Sleator EK (1977), Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 198:1274-1276
140. Swanson J (1992), School-Based Assessments and Interventions for ADD Students. Irvine, CA: KC Publishing
141. Swanson J (1993), Effect of stimulant medication on hyperactive children: a review of reviews. Except Child 60:154-162
142. Swanson J, Greenhill L, Pelham WE et al. (2000), Initiating Concerta® (OROS methylphenidate HCL) qd in children with attention-deficit/ hyperactivity disorder. J Clin Res 3:59-76
143. Swanson J, Gupta S, Guinta D et al. (1999a), Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295-305
144. Swanson J, Kinsbourne M, Roberts W, Zucker K (1978), Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 61:2-29
145. Swanson J, Lerner M, Williams L (1995), More frequent diagnosis of attention deficit-hyperactivity disorder. N Engl J Med 333:944
146. Swanson J, Volkow N (2000), Pharmacodynamics and pharmacokinetics of stimulants in AD/HD In: The Neuropharmacology of Psychostimulant Drugs: Implications for AD/HD, Solanto M, Castellanos X, eds. New York: Oxford University Press, pp 101-125
147. Swanson J, Wigal S, Greenhill L et al. (1998), Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 37:1-8
148. Swanson JM, Connor DF, Cantwell D (1999b), Combining methylphenidate and clonidine: ill-advised. J Am Acad Child Adolesc Psychiatry 38:617-619
149. Tannock R, Ickowicz A, Schachar R (1995a), Differential effects of MPH on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 34:886-896
150. Tannock R, Schachar R, Logan GD (1995b), Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J Abnorm Child Psychol 23:235-267
151. Thurber S, Walker C (1983), Medication and hyperactivity: a meta-analysis. J Gen Psychiatry 108:79-86
152. Varley C (2000), Sudden death of a child treated with imipramine. J Child Adolesc Psychopharmacol 10:321-325
153. Varley CK, McClellan J (1997), Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 36:390-394
154. Vitiello B, Burke L (1998), Generic methylphenidate versus brand Ritalin: which should be used? In: Ritalin: Theory and Practice, Greenhill L, Osman B, eds. Larchmont, NY: Mary Ann Liebert, pp 221-226
155. Vitiello B, Jensen P (1997), Medication development and testing in children and adolescents. Arch Gen Psychiatry 54:871-876
156. Volkow N, Ding J, Fowler G et al. (1995), Is methylphenidate like cocaine? Arch Gen Psychiatry 52:456-464
157. Volkow N, Wang G, Fowler J et al. (1998), Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331
158. Wallace AE, Kofoed LL, West AN (1995), Double-blind, placebo-controlled trial of methylphenidate in older, depressed medically ill patients. Am J Psychiatry 152:929-931
159. Weiner N (1991), Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: The Pharmacological Basis of Therapeutics: Norepinephrine, Epinephrine and the Sympathomimetic Amines, Gilman A, Goodman L, eds. New York, pp 145-180
160. Wender P, Reimherr F (1990), Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 147:1018-1020
161. Wender P, Reimherr F, Wood D (1985), A controlled study of methylphenidate in the treatment of attention deficit disorder. Am J Psychiatry 142:547-552
162. Wender P, Wood D, Reimherr F, Ward M (1994), An open trial of pargyline in the treatment of adult attention deficit disorder, residual type. Psychiatry Res 9:329-336
163. Wender PH, Reimher F, Wood D (1981), Attention deficit disorder in adults. Arch Gen Psychiatry 38:449-456
164. Wigal S, Gupta S, Guinta D, Swanson J (1998), Reliability and validity of the SKAMP Rating Scale in a laboratory school setting. Psychopharmacol Bull 34:47-53
165. Wilens T, Biederman J, Spencer T (1994a), Comorbidity of attention-deficit hyperactivity and psychoactive substance use disorders. Hosp Community Psychiatry 45:421-426
166. Wilens T, Biederman J, Spencer T (1994b), Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 33:424-427
167. Wilens T, Biederman J, Spencer T et al. (1999), A pilot controlled trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention-deficit/hyperactivity disorder. Am J Psychiatry 156:1931-1937
168. Wilens TE, Biederman J (1992), The stimulants. Psychiatr Clin North Am 15:191-222
169. Wilens TE, Spencer TJ (1999), Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 38:614-616
170. Wolraich M, Greenhill LL, Abikoff H et al. (2001), Randomized controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 108:883-892
171. Yee JD, Berde CB (1994), Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 9:122-125
172. Zametkin AJ, Nordahl TE, Gross M et al. (1991), Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 323:1361-1366
173. Zametkin AJ, Rapoport JL (1987), Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 26:676-686
174. Zito J, Safer D, dosReis S, Gardiner J, Boles M, Lynch F (2000), Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030